REVIEW ARTICLE |
|
Year : 2012 | Volume
: 11
| Issue : 1 | Page : 1-15 |
|
Schistosomiasis ( chemoprophylaxis and treatments)
Magdy I El-Zahar, Somaia El-Karim
Department of Therapeutical Chemistry, National Research Centre, Pharmaceutical and Drug Industries Research Division, Cairo, Egypt
Correspondence Address:
Magdy I El-Zahar Department of Therapeutical Chemistry, National Research Centre, Pharmaceutical and Drug Industries Research Division, El-Bohowth St., P.O. Box 12622, Dokki, Cairo Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.7123/01.EPJ.0000415037.38143.d4
|
|
Schistosomiasis is a chronic parasitic disease affecting about 207 million individuals worldwide. It is still a major health problem in many tropical and subtropical countries, as well as for travelers from developed countries. The treatment strategies of schistosomiasis can be divided into two main routes: (a) chemotherapy treatment including trivalent antimony compounds, hycanthone mesylate, niridazole, metrifonate, oxamniquine, oltipraz, artemisinins, albendazole, amoscanate mirazid, and praziquantel; (b) vaccines that may play an important role in the control of schistosomiasis in the future. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|